spacer
home > ebr > autumn 2017 > editors letter
PUBLICATIONS
European Biopharmaceutical Review

Editors Letter

Since our last edition of EBR went to print, there have been significant innovations in new medicines, including those for heart disease, with the anti-inflammatory canakinumab (anti-interleukin-1 beta/ ACZ885) described in the media as the ‘biggest breakthrough in cardiovascular medicine since statins...’ (1). Additionally, the milestone approval of Kymrhia (tisagenlecleucel) in the US, the first chimerical antigen receptor (CAR) T-cell therapy for blood cancers, heralds “a new frontier” of medicine, according to Scott Gottlieb at the FDA (2). These are exciting new next-generation biopharmaceuticals, biological and advanced therapy medicinal products (ATMPs), the latter being the ultimate in personalised medicine, generated from the patient’s own lymphocytes.

A key component of the successful and, arguably, much more established drug development pathways for small molecules that require first pass liver metabolism is an understanding of their metabolism and kinetic properties, from both a safety and efficacy perspective. Dr Richard Weaver FRSC of XenoGesis Ltd highlights the importance of early expertise in drug metabolism and pharmacokinetics and absorption distribution metabolism elimination properties for development pathways. Meanwhile, Optibrium Ltd’s Matthew Segall looks at the role of mathematical and computational modelling of cytochrome P450 interactions.

For any therapy employing human tissue systems at the preclinical phase of development – such as the 3D organoid introduced by QGel’s Dr Colin Sanctuary or the tailored, precision medicine tissue systems the Glasgow-based Aridhia, ReproCELL Europe and Stratified Medicine Scotland team are continuing to pioneer – can better predict drug response outcomes in terms of safety and efficacy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pharmaceutical and Medical Industry Increasingly Demands Automated Testing Solutions

After the manufacturing processes in pharmaceutical and medical industries reached a high level of automation in recent years, manufacturers are more committed to automating their testing processes as well. Production-related tests as well as tests for product release are to be largely automated. In addition to higher specimen throughput, an increase in reproducibility through the elimination of operator influence is a main objective for manufacturers. Zwick Roell offers various levels of automation for testing syringes, insulin pens, and auto injectors.
More info >>

White Papers

Stripping the confusion out of PVC curtains... and a new seat range.

Teknomek Ltd

With the ever-growing trend towards modularisation of clean rooms and laboratories; Teknomek have responded with a new range of PVC strip curtains, suitable for use in environments where maintaining clean airflow is critical. This new PVC curtain range includes specialist perforated and electrostatic discharge alternatives to the standard options of clear and polar (-25oC) versions.
More info >>

 
Industry Events

10th Annual Summit for Clinical Ops Executives

18-21 February 2019, Hyatt Regency Orlando, Florida

Celebrating its 10th successful year, SCOPE Summit 2019 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 19 different conferences, 3 plenary keynote sessions, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including...
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement